The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases ...
Combining proteasome inhibitors with autophagy inhibitors disrupts acute myeloid leukemia (AML) cells' proteostasis, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback